RE:what shall i doDefinitely CXR. Although VRX may be coming back (maybe not), there is still some negative stigma attached. Some are also concerned about potential drug price slashing. CXR has top notch, transparent management that does not rely on hiking drug prices. I am not saying VRX's management is not competent or anything of the sort, I am just confident that Concordia's is. There is very large upside to both in my opinion, but CXR appears to be a safer bet. A large pipeline of drugs and ample cash flow to pay down debt. Nothing but good things to come for CXR whereas the jury is still out on Valeant. Good luck and I hope you do your DD and make an informed decision!